Drug Profile
MYK 224
Alternative Names: BMS-986435; HCM-2; MYK 224Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator MyoKardia
- Developer Bristol-Myers Squibb; MyoKardia
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Cardiac myosin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure; Hypertrophic cardiomyopathy
Most Recent Events
- 13 Nov 2023 Bristol-Myers Squibb plans the AURORA-HFpEF phase II trial of MYK 224 for Heart failure (In adults, In the elderly) in November 2023 (NCT06122779) (EudraCT2023-505919-21)
- 07 Nov 2023 Phase-II clinical trials in Heart failure (In adults, In the elderly) in USA (unspecified route) (NCT06122779)
- 11 Jun 2023 Bristol-Myers Squibb completes a phase I pharmacokinetics trial in USA (NCT05686096)